Willow Biosciences (TSX:WLLW) Partners with API Manufacturer for Sustainable Ingredient Development

2 min read | September 20, 2024 03:57 AM EDT | By Team Kalkine Media

Google News:

Willow Biosciences (TSX:WLLW) Partners with API Manufacturer for Sustainable Ingredient Development — Image source: © Pattanaphongphoto | Megapixl.com

Recent News

Why Is Canadian Natural Resources (TSX:CNQ) Leading S&P/TSX 60 Energy...

Why Is Canadian Natural Resources (TSX:CNQ) Steady in TSX 60?

Why Is Brookfield (TSX:BN) Helping Stabilize the S&P/TSX 60?

Why Is Brookfield Infrastructure (TSX:BIP.UN) Advancing Its Digital As...

Make Kalkine Media
My Trusted Source

Willow Biosciences Inc. (TSX:WLLW), a pioneering biotechnology company dedicated to transforming the industrial manufacturing landscape, has announced a new collaboration with a prominent Active Pharmaceutical Ingredient (API) manufacturer. This partnership aims to develop a more sustainable and cost-effective manufacturing route for a high-volume ingredient used in a therapeutic with a global market exceeding $1 billion. This initiative represents the second program between the two organizations, following their initial collaboration announced on January 31, 2024.

Innovative Solutions for Pharmaceutical Manufacturing

The API manufacturer, which currently markets the target ingredient, has engaged Willow's expertise to devise an enzyme-based solution to replace a complex large-scale chemical process. This innovative approach is expected to streamline production, making it both more sustainable and economically viable. The development phase of this collaboration is anticipated to span approximately six months, during which Willow will work towards achieving specific performance targets. Successful milestones could lead to additional payments, potentially commencing as early as 2025.

A Growing Portfolio of Partnerships

This latest API partnership marks Willow’s fourth announced commercial agreement of the year, reflecting the company's robust growth strategy and commitment to forging impactful collaborations. Each of these agreements includes milestone payments or other commercial opportunities that could start generating revenue as soon as next year, further solidifying Willow’s position in the biotechnology sector.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Incorporated (Kalkine Media), Business Number: 720744275BC0001 and is available for personal and non-commercial use only. The advice given by Kalkine Media through its Content is general information only and it does not take into account the user’s personal investment objectives, financial situation and specific needs. Users should make their own enquiries about any investment and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media is not registered as an investment adviser in Canada under either the provincial or territorial Securities Acts. Some of the Content on this website may be sponsored/non-sponsored, as applicable, however, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used in the Content unless stated otherwise. The images/music that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.